tetano
Editor, Senior Moderator
Cells
. 2021 Oct 14;10(10):2755.
doi: 10.3390/cells10102755.
Quantifying Renin-Angiotensin-System Alterations in COVID-19
Fabrizio Pucci[SUP] 1 2 [/SUP], Filippo Annoni[SUP] 3 [/SUP], Robson Augusto Souza Dos Santos[SUP] 4 [/SUP], Fabio Silvio Taccone[SUP] 3 [/SUP], Marianne Rooman[SUP] 1 2 [/SUP]
Affiliations
Abstract
The renin-angiotensin system (RAS) plays a pivotal role in a wide series of physiological processes, among which inflammation and blood pressure regulation. One of its key components, the angiotensin-converting enzyme 2, has been identified as the entry point of the SARS-CoV-2 virus into the host cells, and therefore a lot of research has been devoted to study RAS dysregulation in COVID-19. Here we discuss the alterations of the regulatory RAS axes due to SARS-CoV-2 infection on the basis of a series of recent clinical investigations and experimental analyzes quantifying, e.g., the levels and activity of RAS components. We performed a comprehensive meta-analysis of these data in view of disentangling the links between the impaired RAS functioning and the pathophysiological characteristics of COVID-19. We also review the effects of several RAS-targeting drugs and how they could potentially help restore the normal RAS functionality and minimize the COVID-19 severity. Finally, we discuss the conflicting evidence found in the literature and the open questions on RAS dysregulation in SARS-CoV-2 infection whose resolution would improve our understanding of COVID-19.
Keywords: ACE2; Angiotensin II; Angiotensin-(1-7); RAS dysregulation; RAS-targeting drugs; SARS-CoV-2; spike protein.
. 2021 Oct 14;10(10):2755.
doi: 10.3390/cells10102755.
Quantifying Renin-Angiotensin-System Alterations in COVID-19
Fabrizio Pucci[SUP] 1 2 [/SUP], Filippo Annoni[SUP] 3 [/SUP], Robson Augusto Souza Dos Santos[SUP] 4 [/SUP], Fabio Silvio Taccone[SUP] 3 [/SUP], Marianne Rooman[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34685735
- PMCID: PMC8535134
- DOI: 10.3390/cells10102755
Abstract
The renin-angiotensin system (RAS) plays a pivotal role in a wide series of physiological processes, among which inflammation and blood pressure regulation. One of its key components, the angiotensin-converting enzyme 2, has been identified as the entry point of the SARS-CoV-2 virus into the host cells, and therefore a lot of research has been devoted to study RAS dysregulation in COVID-19. Here we discuss the alterations of the regulatory RAS axes due to SARS-CoV-2 infection on the basis of a series of recent clinical investigations and experimental analyzes quantifying, e.g., the levels and activity of RAS components. We performed a comprehensive meta-analysis of these data in view of disentangling the links between the impaired RAS functioning and the pathophysiological characteristics of COVID-19. We also review the effects of several RAS-targeting drugs and how they could potentially help restore the normal RAS functionality and minimize the COVID-19 severity. Finally, we discuss the conflicting evidence found in the literature and the open questions on RAS dysregulation in SARS-CoV-2 infection whose resolution would improve our understanding of COVID-19.
Keywords: ACE2; Angiotensin II; Angiotensin-(1-7); RAS dysregulation; RAS-targeting drugs; SARS-CoV-2; spike protein.